scispace - formally typeset
F

Filip K. Knop

Researcher at University of Copenhagen

Publications -  523
Citations -  17834

Filip K. Knop is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 61, co-authored 437 publications receiving 13614 citations. Previous affiliations of Filip K. Knop include Copenhagen University Hospital & Victor Chang Cardiac Research Institute.

Papers
More filters
Journal ArticleDOI

The unobtainable placebo: control of independent clinical research by industry?

TL;DR: The present situation shows that, without a legal obligation to provide placebos to match their marketed drugs, the pharmaceutical industry has de-facto control over drug trials.
Journal ArticleDOI

Hepatic microbiome in healthy lean and obese humans.

TL;DR: Evidence is provided for the presence of bacterial rDNA in the healthy human liver and it is proposed that the increased bacterial DNA load in the livers of obese individuals could constitute an early risk factor for the progression of NAFLD.
Journal ArticleDOI

Effects of Smoking Versus Nonsmoking on Postprandial Glucose Metabolism in Heavy Smokers Compared With Nonsmokers

TL;DR: It is suggested that smoking in association with meal intake decreases the postprandial plasma glucose concentrations, possibly through decreased gastric emptying, and that elevated fasting glucagon concentrations rather than smoking-induced alterations in postPRandial glucose and hormone responses may be associated with the elevated risk of type 2 diabetes in chronic smokers.
Journal ArticleDOI

Increased Postprandial Response of Glucagon-Like Peptide-2 in Patients with Chronic Pancreatitis and Pancreatic Exocrine Insufficiency

TL;DR: The results suggest that delayed assimilation of nutrients in patients with chronic pancreatitis and PEI increases the secretion of GLP-2 – possibly due to delivery of a larger nutrient load to the distal part of the small intestine, whereglucagon-like peptide-2 secreting L-cells are abundant – and that this hypersecretion of GLp-2 is associated with a higher SMA flow.